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Abstract
Neurotransmitters formed in the cytosol of presynaptic nerve endings are 
enclosed in transport vesicles, which are then transported toward plasma 
membrane. Through interaction with SNARE proteins, transport vesicles 
fuse with plasma membrane to release neurotransmitters into the syn-
aptic space. SNARE proteins are targets of botulinum toxins (BoNTs) and 
tetanus toxin. All types of BoNTs consist of a heavy chain and a light 
polypeptide joined by a disulfide bond. The light chain possesses pro-
tease activity. Once inside the cytosol, the light chain is released to cleave 
the specific component of SNARE protein responsible for transmitter exo-
cytosis. Type A and E cleave to SNAP-25. Cleavage of SNARE protein pre-
vents exocytosis of neurotransmitters, resulting in chemo-denervation. 
BoNT is known to inhibit the release of acetylcholine from cholinergic 
nerve terminals in the neuromuscular junctions of striated muscle. BoNT/
A has been found to reduce the release of norepinephrine from the ure-
thra. The release of CGRP and substance P is also found to be inhibited 
by BoNT. Stimulated release of ATP, a mediator for nociception of urinary 
bladder, from urothelial cells of cyclophosphamide-induced inflammatory 
rat bladders was significantly reduced by BoNT/A. Release of some neuro-
transmitters, including neuropeptide Y and nitric oxide, is not affected by 
BoNTs. BoNTs might influence the presentation of membrane receptor. 
BoNT/A has been found to reduce the expression of adrenergic receptor 
in rat prostate. Higher dose of BoNT/A might cleave the SNARE protein 
responsible for receptor trafficking, with a resultant reduction in recep-
tor presentation on plasma membrane. Lethal BoNT dose for humans 
is unknown, but referencing data derived from animal research, one 
would suspect a LD50 of BoNT/A for a 70-kg human to be around 3000 U. 
Botulism-like side effects are prone to occur in patients with neurological 
disorder. Serious systemic side effects from BoNT/A injection into the 
lower urinary tract are not common. Only a few cases of generalized weak-
ness have been reported. Active UTI and known hypersensitivity to BoNTs 
prohibit BoNT application. Drugs affecting neuromuscular transmission, 
such as aminoglycosides, should not be used concurrently. Decreased 
detrusor contractility is expected following bladder injection of BoNT. 
Patients with significant bladder outlet obstruction should be informed of 
the possibility of urinary retention with a need for intermittent catheteri-
zation after BoNT administration. [Tzu Chi Med J 2007;19(3):109–114]
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1.  Mechanism of neurotransmitter 
release from presynaptic nerve 
endings
The neurotransmitters formed in the cytosol of pre-
synaptic nerve endings are enclosed in transport 
vesi cles, which are then transported toward the 
plasma membrane. Through interaction with SNARE 
(N-ethylmaleimide-sensitive factor attachment pro-
tein receptor) proteins, transport vesicles fuse with 
the plasma membrane to release neurotransmitters 
into the synaptic space, a process called regulated 
exocytosis. SNARE proteins are a large protein super-
family consisting of more than 60 members. Upon 
fusion, SNARE proteins form a 4-alpha-helix bundle, 
con sisting of synaptobrevin, syntaxin and two 25 kD 
synaptosomal associated proteins (SNAP-25). Without 
an intact SNARE protein complex, neurotransmitter-
containing vesicles cannot fuse with the plasma mem-
brane to release neurotransmitters. SNARE proteins 
are targets of botulinum toxins (BoNTs) and tetanus 
toxin [1,2].
2.  Structure and action mechanisms 
of BoNTs
There are seven serotypes of BoNT: A, B, C1, D, E, F 
and G. Only A, B, E and F are poisonous to humans. 
All types consist of a heavy chain and a light polypep-
tide joined by a disulfide bond. The light chain pos-
sesses protease activity. The heavy chain involves the 
binding with BoNT receptors located on the plasma 
membrane to facilitate endocytosis of the toxin mol-
ecule. The receptor for BoNTs was not fully recognized 
until recently. Dong et al identified synaptic vesicle 
protein SV2 as the membrane receptor for botuli-
num toxin A (BoNT/A) [3]. Receptors for other types 
of BoNTs remain to be determined.
Once inside the cytosol, the light chain is released 
to cleave the specific component of the SNARE protein 
responsible for transmitter exocytosis. Each serotype 
of BoNT has its own specific cleavage site on the 
SNARE protein. Types A and E cleave to SNAP-25; 
types B, D, F, and G cleave to synaptobrevin, and type 
C1 to syntaxin. Cleavage of the SNARE protein pre-
vents exocytosis of neurotransmitters, resulting in 
chemo-denervation [4,5].
3.  Release of what neurotransmitter is 
inhibited by BoNT?
Classically, BoNT is known to inhibit release of ace-
tylcholine from cholinergic nerve terminals in the 
neuromuscular junction of striated muscle. It is now 
known that acetylcholine release can also be inhibited 
from parasympathetic nerve endings of exocrine 
glands. Ellies et al demonstrated that BoNT decreased 
acetylcholinesterase expression in the submandibu-
lar glands of rats [6]. In addition, decreased release 
of acetylcholine from the rat detrusor was found 
following BoNT A injection [7].
Whether adrenergic neurotransmitter release is 
modified by BoNT is controversial. An earlier study 
on brain synaptosome could not show a decrease in 
potassium-stimulated release of norepinephrine [8]. 
However, later studies showed inhibitory effects of 
BoNT on the release of norepinephrine from brain 
neurons [9,10].
BoNT/A has been found to reduce the release of 
norepinephrine from nerve endings in smooth mus-
cles. Morris et al demonstrated that isometric con-
tractions of isolated vena cava to field stimulation at 
20 Hz, mediated by norepinephrine, were reduced sig-
nificantly by BoNT/A [11]. Smith et al also found that 
norepinephrine release from the urethra induced by 
high frequency electrostimulation was inhibited by 
BoNT/A for at least 30 days after injection [7].
The release of calcitonin gene related peptide 
(CGRP), a sensory neurotransmitter, is also found to 
be inhibited by BoNT. Durham et al showed that the 
stimulated release of CGRP from cultured trigeminal 
neurons was greatly reduced by BoNT/A [12]. Chuang 
et al also found that intravesical BoNT/A adminis-
tration blocked acetic acid-induced bladder pain 
responses and inhibited CGRP release from afferent 
nerve terminals [13].
BoNT/A is also capable of inhibiting the release 
of substance P. Welch et al found that substance P 
secretion was reduced by BoNT/A in embryonic rat 
dorsal root ganglia neurons that exhibited calcium-
dependent substance P secretion when depolarized 
with elevated extracellular potassium [14].
Not only do BoNTs inhibit the release of neuro-
transmitters from nerve endings and neurons, some 
of them also prevent the release of neurotransmit-
ters from other type of cells. Smith et al found that 
stimulated release of ATP, a mediator for nocicep-
tion in the urinary bladder, from urothelial cells in 
rat bladders with cyclophosphamide-induced inflam-
mation was significantly reduced by BoNT/A [15]. 
The authors proposed that exocytosis of ATP from 
urothelial cells required SNARE proteins, which were 
cleaved by BoNT/A. However, this hypothesis needs 
further verification since there is no clear evidence 
showing the existence of BoNT receptors on urothe-
lial cells. Besides, the exact mechanisms involving 
ATP release from urothelium remain uncertain [16].
Release of some neurotransmitters is clearly not 
affected by BoNTs. Morris et al found that sustained 
field-stimulated contractions of guinea pig vena 
cava mediated by neuropeptide Y were not affected 
by BoNT/A [11]. In another study, Morris et al 
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demonstrated that although field-stimulated contrac-
tion of the guinea pig uterine artery was markedly re -
duced by BoNT/A, nitric oxide-induced relaxation was 
not affected. These results indicate that nitric oxide 
release does not go through exocytosis or that nitric 
oxide release is not SNARE protein dependent [17]. 
Olgart et al also found that nitric oxide release from 
guinea pig intestine could not be inhibited by BoNT/
B, indicating the non-vesicular nature of nitric oxide 
release [18]. We also found that in canine prostate 
strips contracted by phenylephrine, field stimulation-
induced relaxation was not changed by BoNT/A injec-
tion, indicating that nitric oxide release in the prostate 
is also not SNARE protein dependent.
4. Target sites of BoNT
Target sites of BoNTs other than the plasma mem-
brane of nerve endings or neurons have been pro-
posed. As indicated in the previous section, urothelial 
cells have been considered to be a target of BoNT/A 
to inhibit the release of ATP [15].
Some studies suggested smooth and striated mus-
cle cells as the targets of BoNTs. James et al demon-
strated that low concentration BoNT/A reduced guinea 
pig pyloric contractions to electric field stimulation 
without affecting acetylcholine-induced contractions. 
However, at higher concentrations (10 U/mL), BoNT 
decreased pyloric contractile responses to both field 
stimulation and acetylcholine administration, indicating 
direct inhibitory effects of BoNT/A on pyloric smooth 
muscle [19].
In rat skeletal muscle 4 weeks after BoNT injec-
tion, vacuoles of variable size were seen in the sar-
coplasm near myonuclei, both at and away from the 
endplates. This phenomenon was not observed fol-
lowing surgical denervation, suggesting direct toxic 
effects of BoNT on skeletal muscle cells [20]. We also 
observed extensive vacuolization of stromal smooth 
muscle cells in dog prostate 4 weeks after injection 
of BoNT/A, further confirming the direct toxic effects 
of BoNT/A on smooth muscle.
5.  Actions of BoNT other than inhibiting 
neurotransmitter release
BoNTs might influence the presentation of membrane 
receptors. Ma et al injected BoNT/A into rat gastroc-
nemius muscle and found that mRNA from nicotinic 
cholinergic receptors was upregulated and then 
returned to normal levels within 2 weeks. This could 
be a compensatory response of treated muscle to the 
blockade of acetylcholine release [21]. However, in 
contrast to Ma et al’s finding, BoNT/A has been found 
to reduce the expression of adrenergic receptors. 
Chuang et al found that 1 week after injection of 
BoNT/A into rat prostate, the amount of alpha 1A 
receptors was dose-dependently reduced [22]. One 
would expect an increase of alpha adrenergic recep-
tors following the BoNT/A-induced decreased cate-
cholamine in the synaptic space as compensation. 
One possibility could be that the trafficking of alpha 
adrenergic receptors from internal pools to the plasma 
membrane is mediated by some SNARE proteins [2]. 
Such machinery has been identified in the case of 
nicotinic receptors [23]. Higher doses of BoNT/A might 
also cleave the SNARE protein responsible for recep-
tor trafficking, resulting in a reduction of receptor 
presentation on the plasma membrane.
6.  Physiological sequences of BoNT 
administration
6.1. Induces atrophy with a decrease in 
contractile function of skeletal muscle
It is well known that BoNT injection reduces con-
tractile function of striated muscle and it has been 
widely used for dystonia, spasticity, strabismus and 
blepharospasm.
6.2. Reduces contractile function of 
smooth muscle
A large number of studies have proved the effective-
ness of BoNT/A injection in reducing the contractile 
function of the smooth muscle of the anal sphincter, 
esophageal gastric junction and urinary bladder in 
the treatment of anal fissures, achalasia and detrusor 
overactivity.
6.3. Induces atrophy with reduced secretion 
from exocrine glands
Clinical studies showed BoNT injection may decrease 
sweating and improve symptoms of hyperhydrosis 
[24–26]. Several papers reported good results in 
treating sialorrhoea with sonography-guided BoNT 
injection into the salivary glands [27,28].
Studies indicated that the prostatic gland is richly 
innervated by cholinergic nerves [29,30]. M3 mus-
carinic receptors were also found in the outer muscle 
layer surrounding the prostatic acini [29]. Theoreti-
cally, prostatic glandular secretion should also be 
depres sed by BoNT. One study did show atrophic 
effects of BoNT/A on rat prostate. One and 2 weeks 
after prostate BoNT injection, there was a significant 
atrophy of the prostate glands with an abundance of 
apoptosis [31]. Similar findings were also observed 
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by Chuang et al [22]. We also saw atrophic changes 
in the glandular component of canine prostate after 
BoNT/A injection (unpublished data).
6.4. Decreases inflammatory response and 
pain provoked by experimental 
inflammation
It has been shown that subcutaneous injection of 
BoNT/A 5 hours to 12 days before injecting formalin 
into the plantar surface of rat hind paw inhibited the 
formalin-induced inflammatory pain response [32]. 
Further study showed that BoNT/A reduced glutamate 
release from the rat footpad and also downregulated 
fos gene expression in the spinal cord [33].
Chuang et al induced prostatitis by injecting cap-
saicin. Pretreatment with BoNT/A reduced polymor-
phonuclear cell infiltration in the prostate with a 
reduction of COX-2 expression. The pain from pros-
tatitis was also diminished by BoNT/A application [34].
7. Adverse effects of BoNTs
7.1. Lethal dose of BoNTs
The potency of BoNTs is expressed in units (U). One 
unit represents the dose fatal to 50% (LD50) of a 
batch of Swiss Webster mice. The lethal dose of BoNT 
for humans remains undetermined. Data on mon-
keys might be applicable to humans. In one study, 
BoNT/A was injected intramuscularly into monkeys. 
An injection of 33 U/kg began to cause systemic toxic-
ity. The LD50 was approximately 39 U/kg body weight 
[35]. Another study found the LD50 of an intrave-
nous injection of BoNT/A in monkeys was 40 U/kg, 
which was similar to that of intramuscular injection 
[36]. Referencing these data, one would suspect an 
LD50 of BoNT/A for a 70 kg human is around 3000 U. 
However, interspecies differences in the susceptibility 
to toxin make it difficult to confirm that this estimate 
is a lethal dose of BoNTs for humans. Nevertheless, 
the maximal dosage clinically used rarely exceeds 
300–400 U, which is far below the lethal dose and is 
unlikely to cause serious systemic side effects.
7.2. Systemic botulism-like side effects
Although botulism-like systemic side effects follow-
ing clinical application of BoNTs is uncommon, it has 
been found by some investigators. In two separate 
reports, following injection of BoNT/A (Dysport), five 
adult patients with dystonia or spasticity developed 
botulism-like symptoms with generalized weakness 
with and without ptosis. The side effects emerged 
from 4 days to 3 weeks after injection and lasted 
for 3–6 months [37,38]. Wyndaele and Van Dromme 
reported two cases of generalized muscle weakness 
following BoNT/A (one with 1000 U Dysport, one with 
300 U Botox) injection into the detrusor muscle [39].
Patients with neurological disorders are prone to 
botulism-like side effects. Wilson reported one case 
of acute myasthenic crisis after a second injection 
for blepharospasm in a patient with motor neuron 
disorder [40].
7.3. Systemic autonomic side effects
Some systemic autonomic side effects of BoNT/A 
have been proposed. Claus et al found that after a 
second injection of BoNT (Dysport) in patients with 
spasmodic torticollis, there were changes in some 
parameters of heart rate variability (HRV). However, 
no clinically significant arrhythmia was found [41]. 
In contrast, Nebe et al found no effects of BoNT on 
HRV [42].
Impaired contractile function of the gallbladder has 
also been found following BoNT injection. Schnider 
et al discovered that in four patients who received 
high dose BoNT/A (Dysport) injections, the empty-
ing function of the gallbladder became abnormal 8 
and 15 days after the injection. Although there were 
no complaints of gastrointestinal symptoms, BoNTs 
should be used cautiously in patients with gallbladder 
disorders [43].
More systemic autonomic side effects were found 
with BoNT/B injection. Dresser et al applied BoNT/B 
to treat cervical dystonia, and 92% of patients 
experienced at least one autonomic side effect, 
such as mouth dryness, swallowing difficulty, and 
constipation [44].
7.4. Side effects of BoNT treatment for 
lower urinary tract dysfunction
Serious systemic side effects from BoNT/A injection 
into the lower urinary tract are not common. Only 
a few cases have been reported. As indicated in a 
previous section, two patients who received BoNT/
A bladder injection experienced generalized weak-
ness [39]. Dykstra and Sidi found that following 
BoNT/A injection into the urethral sphincter, three 
patients with detrusor sphincter dyssynergia experi-
enced mild generalized weakness, which lasted for 
2–3 weeks [45].
Only a few studies have used BoNT/B in the lower 
urinary tract. In one study, four of 20 patients receiv-
ing BoNT/B bladder injections for detrusor overac-
tivity experienced side effects, including dry mouth, 
constipation and generalized weakness [46].
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7.5. Factors related to the occurrence of 
side effects
The serotypes of the BoNTs, formulation, dilution fac-
tor, injection technique, and individual susceptibility 
may all influence the occurrence of side effects with 
BoNT injection.
8.  Contraindications and cautions in 
BoNT administration
Active urinary tract infection precludes urethral instru-
mentation for bladder and urethral injection. Prostate 
injections, either transurethrally or transperineally, 
are also not suitable for patients with urinary tract 
infection.
Of course, known hypersensitivity to BoNTs pro-
hibits BoNT application. Although one patient with 
myasthenia gravis has been treated safely with BoNT, 
BoNT injection is generally not recommended for 
patients with neuromuscular disorders; side effects 
in patients with neuromuscular disorders have been 
noted [47]. Drugs affecting neuromuscular transmis-
sion, such as aminoglycosides, should not be used 
concurrently.
Decreased contractile function of the detrusor is 
expected following bladder injection of BoNT. Patients 
with significant bladder outlet obstruction should be 
informed of the possibility of urinary retention with 
a need for intermittent catheterization after BoNT 
administration.
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